Department of Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Department of Pathology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt.
Asian Pac J Cancer Prev. 2023 Jul 1;24(7):2305-2311. doi: 10.31557/APJCP.2023.24.7.2305.
Detecting thyroid tumors depends on histologic characteristics. However, distinguishing malignant from benign thyroid abnormalities may be challenging and contentious, particularly in tumors with a follicular appearance. Therefore, immunohistochemistry might be useful and essential. Immunohistochemical biomarkers, such as human trophoblast cell surface antigen (TROP) and Hector Battifora Mesothelial-1 (HBME-1), have helped diagnose thyroid cancers. In addition, mesothelial cells have an antigen called HBME-1 on their membranes, but its role is unclear. Thyroid epithelial neoplasms have lately been studied, and TROP-2 is a helpful marker of these tumors. Recently, researchers have explored HBME-1 upregulation in benign and malignant thyroid tumors. This research aimed to show that the immunohistochemical biomarkers TROP-2 and HBME-1 might be employed to distinguish malignant from benign follicular-derived thyroid lesions.
The research consisted of 50 specimens of various follicular thyroid lesions. From October 2018 to March 2021, blocks of follicular thyroid lesions and clinical information were collected from the Pathology Departments of Al-Azhar University Hospitals. Additionally, the HBME-1 and TROP-2 antigens were stained immunohistochemically.
Expression of TROP-2 along with HBME-1 distinguished benign from malignant follicular-derived thyroid lesions with respective sensitivities of 74.2 and 87.1% and specificities of 84.2 and 78.9%. Furthermore, positive HBME-1 expression was significantly less prevalent in benign lesions (15.8%) than in malignant lesions (74.2%) (P-value <0.001). Moreover, positive TROP-2 expression was significantly lower in benign lesions (21.1%) than in malignant lesions (87.1%) (P-value <0.001). The P value of <0.001 indicated an extremely strong positive correlation between HBME-1 and TROP-2 expression across all instances investigated.
With high sensitivity and specificity, both HBME-1 and TROP-2 are beneficial in identifying thyroid cancer, particularly papillary carcinoma, and separating malignant follicular-derived thyroid lesions from benign ones.
甲状腺肿瘤的检测取决于组织学特征。然而,区分甲状腺良恶性病变可能具有挑战性,特别是在具有滤泡外观的肿瘤中。因此,免疫组织化学可能是有用和必要的。人类滋养细胞表面抗原(TROP)和 Hector Battifora 间皮素-1(HBME-1)等免疫组织化学生物标志物已有助于诊断甲状腺癌。此外,间皮细胞的膜上有一种称为 HBME-1 的抗原,但它的作用尚不清楚。甲状腺上皮肿瘤最近得到了研究,TROP-2 是这些肿瘤的有用标志物。最近,研究人员探索了 HBME-1 在良性和恶性甲状腺肿瘤中的上调。本研究旨在表明,免疫组织化学生物标志物 TROP-2 和 HBME-1 可用于区分恶性和良性滤泡源性甲状腺病变。
该研究包括 50 例不同滤泡性甲状腺病变标本。2018 年 10 月至 2021 年 3 月,从艾资哈尔大学医院病理科收集滤泡性甲状腺病变的组织块和临床信息。此外,还对 HBME-1 和 TROP-2 抗原进行了免疫组织化学染色。
TROP-2 与 HBME-1 的表达可区分良性和恶性滤泡源性甲状腺病变,其敏感性分别为 74.2%和 87.1%,特异性分别为 84.2%和 78.9%。此外,良性病变中 HBME-1 的阳性表达明显少于恶性病变(分别为 15.8%和 74.2%)(P 值<0.001)。此外,良性病变中 TROP-2 的阳性表达明显低于恶性病变(分别为 21.1%和 87.1%)(P 值<0.001)。P 值<0.001 表明,在所有研究的病例中,HBME-1 和 TROP-2 的表达之间存在极强的正相关关系。
HBME-1 和 TROP-2 的敏感性和特异性均较高,有助于识别甲状腺癌,特别是乳头状癌,并将恶性滤泡源性甲状腺病变与良性病变区分开来。